CAR T cellshematological malignanciesreviewThe current standard of care in hematological malignancies has brought considerable clinical benefits to patients. However, important bottlenecks still limit optimal achievements following a current medical practice. The genetic complexity of the diseases and the ...
In an interim analysis of an ongoing phase 1 trial of CAR T cells targeting EGFR and IL13Ra2 in patients with multifocal, recurrent glioblastoma, intrathecal delivery is feasible and well tolerated, with some reductions seen in tumor size. Stephen J. Bagley , Meghan Logun & Donald M. O’Ro...
J. et al. IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia. Leukemia 29, 415–422 (2015). CAS PubMed Google Scholar Ueda, T. & Kaneko, S. In vitro differentiation of T cell: from CAR-modified T-iPSC. Methods Mol...
The two most common approaches revolve around genetically engineering T cells to introduce either a new T-cell receptor (TCR) or a chimeric antigen receptor (CAR) (Humphries 2013). Adoptive T-cell therapy involves removing a patient's T cells, modifying them ex vivo, and then reinfusing the...
1 Since 2017, a new T cell therapy, chimeric antigen receptor-T (CAR-T) cells have been licensed outside clinical trials. CAR-T cells have extremely potent antitumour activity, but also have a profile of toxic side effects not seen before. Cytokine release syndrome (CRS) and CAR-T cell...
cells by producing interleukin 2 (IL-2) and IL-21, which cause the activation of NK cells and T cells [16]. The CAR structure, when added to the NKT cell, creates a powerful cell with different cytotoxic features against cancers.
A key finding was that cancer patients' T cells were much more easily over-stimulated at antigen doses commonly used during CAR-T cell manufacturing than "healthy" T cells. This made them lose their functionality, or become more "exhausted" as immunologists say, and decreased their ability to...
T cells. NK cells and macrophages are the major players of innate immune cells in solid tumors [15]. NK cells share a similar cytotoxic function with CD8-positive cells by releasing perforin and granzyme. CAR-NK cells have antigen-independent and antigen-dependent tumor-killing capacities ...
Chimeric antigen receptor (CAR) T cell therapy, in which a patient’s own T lymphocytes are engineered to recognize and kill cancer cells, has achieved striking success in some hematological malignancies in preclinical and clinical trials, resulting in s
Herein, we present the design of light-switchable CAR (designated LiCAR) T cells that allow real-time phototunable activation of therapeutic T cells to precisely induce tumour cell killing. When coupled with imaging-guided, surgically removable upconversion nanoplates that have enhanced near-infrared-...